Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review. (July 2015)

• Record Type: Journal Article
• Authors: Wagner, N.; Wyler-Lazarevic, C.A.; Yerly, S.; Samer, C.; Peytavin, G.; Posfay-Barbe, K.M.; Calmy, A.; Ambrosioni, J.
• Is Part Of: New microbes and new infections. Volume 6(2015)
• Page Start: 1
• Page End: 4
• Publication Date: 2015-07
• Subjects: Children -- dolutegravir -- multidrug-resistant human immunodeficiency virus -- rescue therapy -- T-20; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; Microbiology -- Periodicals; Communicable Diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1016/j.nmni.2015.02.003
• Languages: English
• ISSNs: 2052-2975

Abstract

Abstract: The management of multidrug-resistant human immunodeficiency virus (MDR HIV) infections in children is particularly challenging due to the lack of experience with new drugs. Dolutegravir, combined with an optimized antiretroviral background therapy, is promising for the treatment of MDR HIV and has been approved recently for adults and adolescents. Data for children are extremely limited. We describe the efficacy, safety and plasmatic levels of a dolutegravir-based, complex active antiretroviral treatment regimen in a severely overweight 11-year-old child infected with an MDR HIV strain.